Navigation Links
New book tutors future presidents and public on science behind the headlines
Date:8/15/2008

Berkeley -- In the event of a standoff between the United States and Iran over uranium enrichment, would Barack Obama, if elected president, know enough about the physics of nuclear weapons to assess the threat?

In leading the nation toward reduced greenhouse gas emissions, would John McCain as president understand which technologies would best decrease America's carbon footprint?

If not, University of California, Berkeley, physicist Richard A. Muller has the answer: a new book, "Physics for Future Presidents" (Norton, 2008) that he's written as a primer for anyone aspiring to the Oval Office.

The book provides the scientific literacy would-be leaders need to challenge ill-informed, partisan advice on science-based issues such as terrorist threats, global warming, the value of manned exploration of space and the dangers of nuclear weapons. With book in hand, candidates and presidents will be able to publicly explain and defend their decisions rather than defer to their science advisors.

"It's hard to think of an issue these days that doesn't have a science or high tech angle to it," said Muller, a professor in UC Berkeley's physics department for 30 years and an experimental physicist and astrophysicist at Lawrence Berkeley National Laboratory. "My real goal is to make the dialogue more based in knowledge and fact, because I think that will cool down the rhetoric and help bring opposite sides of the political spectrum together to reach agreement."

A big reason such a book is needed is the current lack of scientists at the highest level of government to advise the president, said Muller, a former MacArthur "genius" Award winner who for 34 years was a member of the Jasons, a group of top-level scientists who advise the U.S. departments of defense and energy as well as NASA on technological issues.

"There used to be a science advisory committee that was in constant contact with the president and was expected to
'/>"/>

Contact: Robert Sanders
rsanders@berkeley.edu
510-643-6998
University of California - Berkeley
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. Great Plains historical stability vulnerable to future changes
2. Gene may hold key to future cancer hope
3. DOE publishes update of plan: Facilities for the Future of Science: A 20-Year Outlook
4. NASA technology helps predict and prevent future pandemic outbreaks
5. Sunbathing tree frogs future under a cloud
6. Methane from microbes: a fuel for the future
7. Setting a course for the future of tissue engineering
8. Air quality forecasts see future in space
9. Oceans Past: A Guide to Oceans Future
10. Building the future -- 21st century nano tools to repair the nervous system
11. Climate change in the Baltic Sea basin -- past, present and future

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/3/2009)... , MADISON, WI, NOVEMBER 4, 2009 -- The world,s...rgy among grape variety, human input, and somethin...the vineyard site, soil, and climate. , Expert...ience in a symposium on Wednesday, Nov. 4 in Pitts...will be presented in two parts at the 2009 Annual ...
(Date:11/3/2009)... , , LAKE ALFRED, FLLaser labeling of fruit and... a low-energy carbon dioxide laser beam is used to...eliminating the need for common sticker-type label...ariety of fruits and vegetables and is being used ...es. It has been been approved in Asia, South Afric...
(Date:11/3/2009)... , , FORT COLLINS, COConsumer interest in new a...by factors including the growth of the "local food...pread reports touting its numerous health benefits... increasing throughout the U.S. , While most gro..." garlic (which is most often imported), varieties...
Breaking Biology News(10 mins):Great wines come from great soils 2Laser etching safe alternative for labeling grapefruit 2Sustainably grown garlic 2Sustainably grown garlic 3Synthetic Genomics Inc and ExxonMobil Research and Engineering Company Sign Exclusive Multi Year Agreement to Develop Next Generation Biofuels Using 13011 1Synthetic Genomics Inc and ExxonMobil Research and Engineering Company Sign Exclusive Multi Year Agreement to Develop Next Generation Biofuels Using 13011 2Synthetic Genomics Inc and ExxonMobil Research and Engineering Company Sign Exclusive Multi Year Agreement to Develop Next Generation Biofuels Using 13011 3EMcision Announces 510 28k 29 Clearance of the Habib EndoHPB its Novel Bipolar RF Device for the Palliation of Biliary and Pancreatic Tumours 13009 1EMcision Announces 510 28k 29 Clearance of the Habib EndoHPB its Novel Bipolar RF Device for the Palliation of Biliary and Pancreatic Tumours 13009 2Beta Release of v3 0 of OpenClinica Clinical Trials Software 13007 1Beta Release of v3 0 of OpenClinica Clinical Trials Software 13007 2Beta Release of v3 0 of OpenClinica Clinical Trials Software 13007 3
...issue of Nature Genetics, is based on data from mo... already known genes, but also discovered ten new ...y size of about 3.5 centimeters. , The analysis p...eral of the identified genes are targeted by the m...er genes. This connection was completely unknown u...
...the May 2008 Pediatric Academic Societies and Asia...icate that childhood and adolescent obesity negati...relates to cardiac health. , Obesity has been inc...rs and obesity in adults has been linked to cardio...dren is also increasing and many cardiovascular di...
...pped their comfortable offices for one of the most...out a challenging field campaign that is seen as t... mission CryoSat will be as accurate as possible. ...y and Canada, are currently in the middle of CryoS...ive three-week experiment programme in the far nor...
Other Biology News:How body size is regulated 2Study supports reason for concern in childhood and adolescent obesity 2Scientists endure Arctic for last campaign prior to CryoSat-2 launch 2Scientists endure Arctic for last campaign prior to CryoSat-2 launch 3
(Date:11/6/2009)...Nov. 6 Calbiotech, Inc. announced ...novative Research (SBIR) Phase I contract by the U...der terms of the agreement, Calbiotech will develo...is of Dengue virus. ,, Dengue virus is a mos...at to military forces deployed to tropical areas o...
(Date:11/5/2009)... 5 GenVec, Inc. (Nasdaq:... the third quarter ended September 30, 2009. GenVe...hare) for the three months ended September 30, 200...r share) in the comparable quarter of 2008. For th...et loss was $14.1 million ($0.15 per share), compa...
(Date:11/5/2009)...sday, November 5, 2009 at 4:30 p.m. Eastern Time ,...-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("On...reported unaudited financial results for the third...and reviewed the Company,s highlights for the thir...d results reflect the operations of OncoGenex Tech...
(Date:11/5/2009)... 5, 2009 Senomyx, Inc. (...etary taste receptor-based technologies to discove... and ingredient supply industries, today provided ...for the third quarter ended September 30, 2009. R... 2009, compared to $4.0 million for the third quar...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14
... in Women,s Health (NPWH) Encourages Women to Get...SHINGTON, Feb. 20 Despite growing awareness of HP...vical cancer, a new survey,released by the Nationa...alth (NPWH) found that many women remain in the da...pite the fact that there is now a vaccine that,can...
...hn,s Disease, Pouchitis and ...era Therapeutics, a,biopharmaceutical company focu...ation of proprietary compounds to treat a broad ra...nounced the completion of a,$35.5 million Series C...estors., New investor Montagu Newhall Associates ...
...627 Million; GAAP EPS $0.34; ...Net Revenue Reaches $2.50 Billion; 2007 GAAP EPS ... CORONA, Calif., Feb. 20 Watson,Pharmaceuticals,...tical,company, today reported fourth quarter and f...r ended December 31, 2007 and provided an outlook ...
Other Biology Technology:Survey Shows Most Women Can't Separate Fact From Fiction When It Comes to Cervical Cancer Prevention 2Survey Shows Most Women Can't Separate Fact From Fiction When It Comes to Cervical Cancer Prevention 3Survey Shows Most Women Can't Separate Fact From Fiction When It Comes to Cervical Cancer Prevention 4Ocera Therapeutics Closes $35.5 Million Series C Financing 2Ocera Therapeutics Closes $35.5 Million Series C Financing 3Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 2Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 3Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 4Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 5Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 6Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 7Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 8Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 9Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 10Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 11Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 12Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 13Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 14Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 15Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 16Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 17Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 18
Streptavidin, PE conjugated/tagged from Invitrogen
GIBCO RPMI Medium 1640; powder from Invitrogen
...5 ml Dynabeads Tosylactivated (4.5 m). Hydrophobi...tive groups. For coupling of antibodies for cell a... on initial coupling with covalent binding of prim...)) occurringovernight. Coupling reactions can be p...
Mouse Anti-Mouse BKBeta2 potassium channel Monoclonal Antibody, Unconjugated, Clone N53/32 from UC Davis/NINDS/NIMH NeuroMab Facility
Biology Products: